Supplementation of Eriocitrin in Intestinal Microbiota

Pre Diabetes Clinical Trial

Official title:

Effect of Chronic Eriocitrin Supplementation on the Intestinal Microbiota of Pre-diabetic and Insulin Resistant Individuals

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03925909
• Other study ID #: SaoPSU 13
• Status: Terminated
• Phase: N/A
• Start date: May 1, 2019
• Est. completion date: March 23, 2020

Study information

• Verified date: March 2020
• Source: São Paulo State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Pre-diabetes is characterized by high plasma concentration of glucose and glycated hemoglobin and is the main risk factor for the development of type 2 diabetes. Several studies show that the intestinal microbiota is intimately linked to cardio-metabolic factors (type 2 diabetes, insulin resistance) when in situations of dysbiosis. Food is a key element for a healthy microbiota, focusing on the consumption of polyphenols that modulate the intestinal environment through its alteration and production of short chain fatty acids, and can thus be a way of reversing situations such as pre- diabetes and insulin resistance. The objective of the study will be to investigate whether chronic supplementation of eriocitrin alters the intestinal microbiota of pre-diabetic and insulin resistant individuals, reversing these situations. This will be done by supplementation of eriocitrin-containing capsules with different dosages in pre-diabetic and insulin resistant individuals. There will be 12 weeks of intervention, with faecal collections, anthropometric and dietary evaluation, and then will be made microbiological analysis to identify the intestinal microbiota and biochemical analysis before and after the intervention. For statistical analysis, normality and homogeneity test (Kolmogorov-Smirnov and Levine test respectively), T-test to compare baseline time between groups and repeated-measures ANOVA (two-way) were used to compare changes within and between groups.

Description:

Individuals of both sexes between 30 and 60 years of age who present fasting glycemia between 100 mg / dL (5,6 mmol / L) and 125 mg / dL (6,9 mmol / L) 50, or concentration of glycated hemoglobin between 5.7% (39 mmol / mole) and 6.4% (47 mmol / mole) 50, or glycemic concentrations in the oral glucose tolerance test between 140mg / dL (7.8 mmol / L) to 199mg / dL (11.0 mmol / L) 50. The study will also include insulin-resistant individuals: insulin above 25 uU / mL, or who present HOMA-IR score above 2.7.

Individuals using supplements (vitamins, bioflavonoids), pregnant women and those who practice intense physical exercise (> 10h / week) will be excluded from the study.

The primary endpoint will be alteration of the microbiota with possible improvement of the glycemic profile, leading to the reversal of pre-diabetes and insulin resistance.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 40
• Est. completion date: March 23, 2020
• Est. primary completion date: August 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 60 Years

Eligibility

Inclusion Criteria:

• 30-60 years

• Increased fasting blood glucose from 6.1 to 7.0 mmol / L or,

• Decreased glucose tolerance of 7 , 8 to 11.1 mmol / L or,

• Glycated hemoglobin with values between 5.7 and 6.4%

Exclusion Criteria:

• Use hypoglycemic, hypolipidemic drugs,

• Use dietary supplements (vitamins, minerals, bioflavonoids, prebiotics, probiotics or other bioactive compounds),

• Exercise intensely (more than 10 hours per week)

• History of cardiovascular diseases , diabetes mellitus, liver and kidney disease.

Related Conditions & MeSH terms

• Glucose Intolerance
• Pre Diabetes
• Prediabetic State

Intervention

Dietary Supplement:
• Eriocitrin
The responsible nutritionists will do 1) Anthropometric Assessment, in which weight data will be collected (kg); height (m); waist circumference (cm), waist circumference (cm) and hip circumference (cm), muscle mass (kg /%) and percentage of fat by means of bioimpedance equipment; 2) Dietary assessment, which will be performed through a 24-hour Food Recall, a 3-day Food Record and a Food Consumption Frequency Questionnaire; 3) Evaluation of the microbiota, for which stool will be collected from the last 24 hours on the day before the beginning of the experiment and at the end of the study (week 12); 3) Biochemical evaluation, which includes the collection of 30 mL of blood to be performed by trained and qualified technicians.

Locations

Country	Name	City	State
Brazil	Sao Paulo State University "Julio de Mesquita Filho"	Araraquara	SP

Sponsors (1)

Lead Sponsor	Collaborator
São Paulo State University

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of change in microbiome	Changes in microbiome before and after administration of the intervention / placebo	0-12 week
Secondary	Rate of change in plasma glucose concentration	Changes in serum 2 hours after oral glucose tolerance test, HbA1c, insulin, HOMA-IR before and after administration of the intervention / placebo	0-12 week